Gilead and Nucleai probe why target-positive tumors can still resist ADCs
recent articles
AIRA Matrix has published a new paper. Read on to learn more about their work. Our paper “A deep learning system for prostate cancer diagnosis and grading in whole slide images of core needle biopsies” has been published in the March...
Proscia and Hamamatsu: Cooperation agreement expands access to unified solution for end-to-end workflow PHILADELPHIA – March 9, 2022 – Proscia®, the leader in digital and computational pathology solutions, and Hamamatsu Photonics K.K.,...
Motic will be at USCAP! USCAP 2022 is Coming Soon! Join us at USCAP 2022! We will be located at booth 638 from March 21st-23rd in Los Angeles, California. There you can experience a personal one-on-one consultation with Motic...
HOUSTON, Texas — An implantable “drug factory” the size of a pinhead could cure a patient’s cancer in less than a week! Those are the findings of a new study by bioengineers at Rice University who say the new treatment can completely...
Tampa, Florida / GlobeNewswire – Digital pathology and cancer informatics provider Inspirata announced today that it has received U.S. Food and Drug Administration (FDA) clearance for its Dynamyx digital pathology software. This clearance...
Researcher Christina Caira reflects on use of AI in Parkinson’s Disease research Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by the degeneration of dopamine releasing regions in the brain....
